KMT2A and acute myeloid leukemia: Figure 5 presents results obtained for daunorubicin, either alone or in combination with ABT-737 (see Supplementary Figure S8 for results obtained for individual AMLs). Healthy mice were injected with 0.5 × 106 bone marrow cells from sick secondary MLL-AF9 mice (3 recipients per AML per treatment arm) and treatment was started 3 days later.